January to March 2026:
HARTMANN increases sales revenues and earnings

Heidenheim, 29 April 2026. HARTMANN started the 2026 financial year with an increase in sales and earnings.

From January to March 2026, HARTMANN recorded organic sales growth of 3.3% compared to the same period of the previous year. Sales revenues increased to EUR 623.9 million. All core segments contributed to this growth.

Adjusted EBITDA stood at EUR 77.3 million, up EUR 6.4 million from the prior-year figure. The adjusted EBITDA margin increased from 11.7% to 12.4%.

Through cost and pricing measures, HARTMANN expects to be able to largely offset rising prices for materials, energy and freight resulting from the war in Iran. Thanks to targeted investments and measures in recent years, supply security in crisis situations has been enhanced.

The Wound Care segment grew, driven in particular by advanced wound care with atraumatic dressings and strong performance in the U.S. By contrast, business in Germany and France was impacted by changes and reductions in reimbursements.

In the Incontinence Management segment, growth was primarily driven by incontinence pants and products for moderate to severe incontinence.

The Infection Management segment also recorded growth. Drivers included products for surface and hand disinfection, surgical sets, and surgical and examination gloves.

The Complementary Group Divisions segment recorded an overall decline compared to the same period of the previous year. This was primarily attributable to Kneipp. In contrast, business at the KOB and CMC Groups remained stable.

For the 2026 financial year, HARTMANN expects the positive development to continue, anticipating moderate organic sales growth and adjusted EBITDA in the range of EUR 270 to 310 million.

Further information on financial topics at HARTMANN can be found (in German) at https://corporate.hartmann.info/en/investor-relations.

The HARTMANN GROUP is one of the leading European providers of professional medical and care products and associated services. Every day, healthcare professionals and patients rely on HARTMANN brands in the segments of Incontinence Management (e.g. MoliCare®), Wound Care (e.g. Zetuvit®, Cosmopor®) and Infection Management (e.g. Sterillium®). This is expressed in our brand promise of “Helps. Cares. Protects.” Founded in 1818, the Company sells its products and solutions in 130 countries around the world.

To learn more about the HARTMANN GROUP, visit www.corporate.hartmann.info.